Skip directly to content

Ultibro®▼ Breezhaler® (indacaterol maleate/glycopyrronium bromide)

What is Ultibro® Breezhaler® and what is it used for?

Ultibro Breezhaler is a medicine that contains two active substances called indacaterol maleate and glycopyrronium bromide. These belong to a group of medicines called bronchodilators. It is available as capsules containing a powder for inhalation.

Ultibro Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a long-term lung disease called chronic obstructive pulmonary disease (COPD). In COPD the muscles around the airways tighten. This makes breathing difficult. This medicine causes the airways to open, making it easier for air to get in and out of the lungs. It is used as a maintenance treatment to relieve symptoms of COPD.

If a patient uses this medicine once a day, it will help to reduce the effects of COPD in everyday life.

The active substances, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing for patients with COPD.

Indacaterol is a long-acting beta-2 agonist. When inhaled, it works by reaching the receptors in the airways and activating them. This causes the muscles of the airways to relax.

Glycopyrronium is a muscarinic-receptor antagonist. It works by blocking some receptors called muscarinic receptors, which control the contraction of muscles. When glycopyrronium is inhaled, it causes the muscles of the airways to relax.

The combined actions of the two active substances helps to keep the airways open and allows the patient to breathe more easily.

The medicine can only be obtained with a prescription.

 

Reference information
  • The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Ultibro Breezhaler.
  • If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for Ultibro Breezhaler these can be found at the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

UK/ULT/17-0728 / Oct 2017